NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 1 sec ago

Request for Information (RFI): Current Capabilities in Automated Data Entry and Extraction from Electronic Health Records

Mon, 2023-12-18 01:28
Notice NOT-CA-24-021 from the NIH Guide for Grants and Contracts

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Fri, 2023-12-15 12:55
Funding Opportunity PAR-24-072 from the NIH Guide for Grants and Contracts. Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences.

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

Fri, 2023-12-15 12:53
Funding Opportunity PAR-24-085 from the NIH Guide for Grants and Contracts. The purpose of this reissuance is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate.

Single Source: The NIGMS Human Genetic Cell Repository (U42 - Clinical Trial Not Allowed)

Fri, 2023-12-15 09:53
Funding Opportunity PAR-24-055 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to support the NIGMS Human Genetic Cell Repository (HGCR). The repository will maintain the current collection of cell cultures and DNA samples and will acquire, characterize, and expand high-quality cell samples and distribute cell lines and extracted DNA to qualified biomedical researchers.

Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

Thu, 2023-12-14 12:03
Funding Opportunity RFA-CA-24-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. To be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.

Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

Thu, 2023-12-14 11:42
Funding Opportunity RFA-CA-24-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion FOAs listed above.

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

Thu, 2023-12-14 11:21
Funding Opportunity RFA-CA-24-017 from the NIH Guide for Grants and Contracts. The goal of this FOA is to advance cancer model systems that recapitulate human immunity in the tumor microenvironment to improve the predictivity of immuno-oncology studies. Proposed research projects must focus on recapitulation of the human immune system in their proposed cancer model using human cells or tissues to regenerate and/or recapitulate the human immune system in in vivo or in vitro immuno-oncology models in a manner that matches or exceeds representation of the human immune system achieved with murine models developed using HFT. Models derived from genetically manipulated immune systems without introduction of human immune lineage cells will not be considered responsive.The FOA will utilize the R33 Exploratory/Developmental Grants Phase II research activity code.

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)

Thu, 2023-12-14 11:08
Funding Opportunity RFA-CA-24-016 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, the emphasis of this FOA is on supporting the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research. To be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Projects proposing the application of existing methods or algorithms where the novelty resides in the biological or clinical question being pursued are not responsive to this solicitation and will not be reviewed.

Notice of Special Interest (NOSI): Research Council of Finland (RCF) National Institutes of Health (NIH) Partnership Program

Thu, 2023-12-14 10:40
Notice NOT-OD-24-040 from the NIH Guide for Grants and Contracts

NIH Operates Under a Continuing Resolution

Thu, 2023-12-14 10:36
Notice NOT-OD-24-039 from the NIH Guide for Grants and Contracts

Bat Immunology Network Research Resource Program (U24 Clinical Trial Not Allowed)

Wed, 2023-12-13 12:48
Funding Opportunity RFA-AI-23-069 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support the development and validation of reagents/tools to support research to characterize cellular and molecular constituents of the bat immune system and for the study of protective innate and adaptive immune mechanisms in bats. The Research Resource Program established by this NOFO will participate within a collaborative research network to advance understanding of the bat immune response.

Bat Immunology Network Research Projects (R01 Clinical Trial Not Allowed)

Wed, 2023-12-13 12:40
Funding Opportunity RFA-AI-23-068 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support research to characterize cellular and molecular constituents of the bat immune system and to understand protective innate and adaptive immune mechanisms in bats. Research projects supported by this NOFO will form a collaborative research network to advance understanding of the bat immune response.

Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)

Wed, 2023-12-13 12:30
Funding Opportunity PAR-24-088 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunities (NOFOs) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds. Through this NOFO, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA) and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.

Pages